Nanoform Finland Oyj
NANOFH.HE operates in the healthcare diagnostics industry, providing products and services related to diagnostic testing and research.
Business. NANOFH.HE is a biotechnology and medical research company primarily engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models typical of the industry. It is headquartered in Finland and is listed on the Nasdaq Helsinki exchange under the ticker NANOFH.HE. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
NANOFH.HE is a biotechnology and medical research company primarily engaged in healthcare diagnostics. The firm operates within the pharmaceuticals and medical research sector, focusing on product-based revenue models typical of the industry. It is headquartered in Finland and is listed on the Nasdaq Helsinki exchange under the ticker NANOFH.HE. Specific details regarding operating segments or geographic revenue breakdowns are not available.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.15, indicating a conservative leverage profile. With 24.002 million euros in cash and equivalents, the company maintains a strong liquidity position despite a negative operating cash flow of -17.663 million euros. The free cash flow is also negative at -15.823 million euros, reflecting ongoing operational cash outflows.
Profitability metrics show a return on equity of -0.4184, indicating a significant loss relative to shareholders' equity. The company reported a net loss of 17.898 million euros, with operating income also in the red at -18.478 million euros. These figures suggest the company is not currently generating positive returns and is operating at a loss.
The company's revenue is concentrated in a single entity, as no segment or geographic breakdown is provided in the available data. This lack of diversification could pose a risk if the primary market or product line experiences a downturn.
Looking ahead, the company is expected to continue facing financial challenges. The current fiscal year is projected to show a continuation of losses, with no significant improvement in the next fiscal year. The negative operating and free cash flows suggest that the company may need to rely on its cash reserves to fund operations in the near term.
Risk factors include the company's negative net income and operating income, which could affect its ability to sustain operations without external financing. The risk assessment indicates low dilution potential, but the company's reliance on cash reserves to cover operational shortfalls could increase financial risk if cash flow does not improve.
Recent financial filings and transcripts do not indicate any major events that would significantly alter the company's financial trajectory. The company's financial position remains stable in terms of liquidity and dilution risk, but its profitability remains a concern.
- The company has a strong liquidity position with 24.002 million euros in cash and equivalents.
- The company is currently operating at a loss, with a return on equity of -0.4184.
- The company's capital structure is conservative, with a low debt-to-equity ratio of 0.15.
- The company's financial outlook remains challenging, with no significant improvement expected in the next fiscal year.
- The company's revenue is not diversified, posing a potential risk if the primary market experiences a downturn.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,17 |
| Revenue | —no estimate | —no estimate | 4,5M EUR |
| Operating income | —no estimate | —no estimate | -14,3M EUR |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- NANOFH.HE Market data — financials · 2026-05-28
- Nanoform Finland Oyj Market data — analyst estimates · 2026-05-28